- Home
- USGO vs ZOM Comparison
USGO vs ZOM Comparison
Compare USGO & ZOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- ZOM
- Stock Information
- Founded
- USGO 2015
- ZOM 2015
- Country
- USGO Canada
- ZOM United States
- Employees
- USGO N/A
- ZOM N/A
- Industry
- USGO Precious Metals
- ZOM Biotechnology: Pharmaceutical Preparations
- Sector
- USGO Basic Materials
- ZOM Health Care
- Exchange
- USGO Nasdaq
- ZOM Nasdaq
- Market Cap
- USGO 129.1M
- ZOM 135.9M
- IPO Year
- USGO 2023
- ZOM N/A
- Fundamental
- Price
- USGO $10.41
- ZOM $0.13
- Analyst Decision
- USGO Strong Buy
- ZOM
- Analyst Count
- USGO 1
- ZOM 0
- Target Price
- USGO $24.00
- ZOM N/A
- AVG Volume (30 Days)
- USGO 59.1K
- ZOM 7.1M
- Earning Date
- USGO 11-13-2024
- ZOM 11-07-2024
- Dividend Yield
- USGO N/A
- ZOM N/A
- EPS Growth
- USGO N/A
- ZOM N/A
- EPS
- USGO N/A
- ZOM N/A
- Revenue
- USGO N/A
- ZOM $26,727,000.00
- Revenue This Year
- USGO N/A
- ZOM $36.75
- Revenue Next Year
- USGO N/A
- ZOM $14.92
- P/E Ratio
- USGO N/A
- ZOM N/A
- Revenue Growth
- USGO N/A
- ZOM 11.33
- 52 Week Low
- USGO $5.00
- ZOM $0.12
- 52 Week High
- USGO $14.46
- ZOM $0.23
- Technical
- Relative Strength Index (RSI)
- USGO 57.57
- ZOM 52.71
- Support Level
- USGO $7.66
- ZOM $0.12
- Resistance Level
- USGO $12.31
- ZOM $0.16
- Average True Range (ATR)
- USGO 1.11
- ZOM 0.01
- MACD
- USGO 0.08
- ZOM 0.00
- Stochastic Oscillator
- USGO 59.14
- ZOM 36.05
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About ZOM Zomedica Corp.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.